Core Viewpoint - The company has shown significant improvement in its operating performance in H1 2025, driven by recovering industry demand and enhanced operational quality [1][2][3]. Group 1: Financial Performance - In H1 2025, the company achieved revenue of 6.5 billion, a year-on-year increase of 15%, and a net profit attributable to shareholders of 560 million, up 206% year-on-year [1]. - In Q2 2025, the company reported revenue of 3.8 billion, a year-on-year increase of 29% and a quarter-on-quarter increase of 43%, with a net profit of 300 million, up 932% year-on-year [1]. - The gross margin for H1 2025 was 21.4%, an increase of 1.2 percentage points year-on-year, while the net margin was 9.6%, up 5.8 percentage points year-on-year [1]. Group 2: Product Segment Performance - In H1 2025, the herbicide segment generated revenue of 4.7 billion, up 11% year-on-year, with a gross margin of 19.3%, an increase of 0.9 percentage points [2]. - The insecticide segment achieved revenue of 1.06 billion, a year-on-year increase of 34%, with a gross margin of 28.2%, up 1.1 percentage points [2]. - The fungicide segment reported revenue of 670 million, a year-on-year increase of 16%, with a gross margin of 24.6%, up 2.4 percentage points [2]. Group 3: Business Model and Future Growth - The Model C business is gaining traction, with its revenue contribution reaching 40.1% in H1 2025, an increase of 2.6 percentage points year-on-year, and a gross margin of 30.2%, up 1.0 percentage points [3]. - The company aims to enhance its To C business share, expand its North American and EU operations, increase the share of insecticides and fungicides, and strengthen its biopesticide segment [3]. - The company is expected to achieve revenues of 15 billion, 17.1 billion, and 19.4 billion in 2025, 2026, and 2027, respectively, with net profits of 1.15 billion, 1.36 billion, and 1.66 billion [4].